Research Analysts’ Weekly Ratings Changes for ResMed (RMD)

A number of firms have modified their ratings and price targets on shares of ResMed (NYSE: RMD) recently:

• 7/16/2026 – ResMed was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $234.00 price target on the stock.
• 7/15/2026 – ResMed had its price target lowered by Mizuho from $235.00 to $220.00. They now have an “outperform” rating on the stock.
• 7/12/2026 – ResMed had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $235.00 price target on the stock, down from $270.00.
• 7/12/2026 – ResMed was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $235.00 price target on the stock, down from $270.00.
• 7/10/2026 – ResMed had its price target lowered by Jefferies Financial Group Inc. from $240.00 to $225.00. They now have a “hold” rating on the stock.
• 7/8/2026 – ResMed had its price target lowered by Royal Bank Of Canada from $321.00 to $276.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – ResMed had its price target lowered by Wells Fargo & Company from $227.00 to $225.00. They now have an “equal weight” rating on the stock.
• 7/1/2026 – ResMed had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 6/22/2026 – ResMed had its price target lowered by KeyCorp from $290.00 to $266.00. They now have an “overweight” rating on the stock.
• 6/17/2026 – ResMed had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $230.00 price target on the stock, down from $286.00.
• 6/15/2026 – ResMed had its price target lowered by Citigroup Inc. from $340.00 to $270.00. They now have a “buy” rating on the stock.
• 5/22/2026 – ResMed was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Thursday, May 14th. ResMed’s dividend payout ratio (DPR) is presently 23.14%.

Insider Buying and Selling at ResMed

In related news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the sale, the chief executive officer directly owned 466,223 shares in the company, valued at $101,893,036.65. This trade represents a 1.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 14,973 shares of company stock worth $3,096,067 in the last quarter. Insiders own 0.65% of the company’s stock.

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.